Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gp100-fowlpox vaccine
- Development stage
- Phase 2
- Lead developer
- National Cancer Institute
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Subcutaneous
01
Overview
The gp100-fowlpox vaccine is a recombinant viral cancer vaccine developed by the National Cancer Institute (NCI) Surgery Branch. It consists of a recombinant fowlpox virus (derived from the POXVAC-TC strain) engineered to express the gp100 (PMEL17) melanoma-associated antigen, a protein frequently overexpressed in melanoma cells. The vaccine is designed to stimulate and expand gp100-specific T-cell populations in vivo. In clinical research, it is primarily used as part of a multi-modal immunotherapy regimen for HLA-A*0201-positive patients with metastatic melanoma, typically following lymphodepleting conditioning and the infusion of adoptively transferred gp100-reactive or TCR-engineered lymphocytes, often in conjunction with high-dose interleukin-2 (IL-2).
- Other names
- recombinant fowlpox-gp100 vaccinegp100-fowlpox vaccinegp-100-fowlpox vaccinegp 100-fowlpox vaccine
02
Targets
PMEL (Melanocyte Protein PMEL)
Beyond the preview
Go deeper on gp100-fowlpox vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gp100-fowlpox vaccine.